| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3877595 | The Journal of Urology | 2005 | 4 Pages |
Abstract
Increased serum Her-2/neu correlates with the presence of metastatic disease and it may indicate an increased risk of death in patients with castrate, metastatic prostate cancer. The detection of serum Her-2/neu is a minimally invasive alternative to tumor sampling for identifying potential candidates for anti-Her-2/neu treatment strategies. Further studies are needed to optimize this assay for application in the clinical setting.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
IMAN OSMAN, MARYANN MIKHAIL, BRIAN SHUCH, MEGAN CLUTE, CAROL D. CHELI, FAROOQ GHANI, ROBERT P. THIEL, SAMIR S. TANEJA,